Schering Gains British Biotech's Marimastat, Drops U.S. Fareston Marketing
Executive Summary
Schering-Plough will assume all European and U.S. regulatory filings for British Biotech's cancer therapy marimastat under a collaboration announced September 7 to develop and market British Biotech's matrix metalloproteinase inhibitors.
You may also be interested in...
Aeterna Neovastat Will Be 12th Antiangiogenesis Drug To Reach Phase III
Aeterna Labs' Neovastat will begin patient enrollment for a Phase III clinical trial in non-small cell lung cancer in March, CEO Eric Dupont reported Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.
Aeterna Neovastat Will Be 12th Antiangiogenesis Drug To Reach Phase III
Aeterna Labs' Neovastat will begin patient enrollment for a Phase III clinical trial in non-small cell lung cancer in March, CEO Eric Dupont reported Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.
British Bio Seeking Partners For Three Projects After Zacutex Termination
British Biotech will focus its discovery research on metallo-enzyme inhibition programs and seek partnerships for several compounds following the discontinuation of the pancreatitis therapy Zacutex (lexipafant), the firm announced March 25.